Skip to main content

Year: 2020

Brookfield Property Partners Reports Third Quarter 2020 Results

Written by Customer Service on . Posted in Public Companies.

All dollar references are in U.S. dollars, unless noted otherwise.BROOKFIELD NEWS, Nov. 06, 2020 (GLOBE NEWSWIRE) — Brookfield Property Partners L.P. (NASDAQ: BPY; NASDAQ: BPYU; TSX: BPY.UN) (“BPY”) today announced financial results for the quarter ended September 30, 2020. “We saw consistent improvement in our operations over the course of the third quarter and, while there may be temporary setbacks as different regions reach different stages of recovery, we are confident that the worst of the economic shutdown is now behind us,” said Brian Kingston, Chief Executive Officer. “Our staff has done an amazing job preparing our buildings for safe re-opening and each day it is gratifying to see more office workers, retailers, customers and visitors returning to our properties around the globe.”Company FFO (CFFO) was $161...

Continue reading

New Publication Shows CareDx’s AlloSure May Be Effective for Monitoring BK Virus in Transplant Patients

Written by Customer Service on . Posted in Public Companies.

Research from Johns Hopkins, University of Maryland, and Cedars Sinai Shows AlloSure May Signal BK Virus Progression in Transplant PatientsSOUTH SAN FRANCISCO, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announces today that the journal Transplantation Direct published Donor-derived cell-free DNA and the Prediction of BK virus-associated Nephropathy, showing AlloSure may be a useful non-invasive test to assess progression of BK virus.BK virus (BKV) is a common viral infection in transplant patients that can lead to BKV-associated nephropathy (BKVAN). This study examined data from the Diagnosing Acute Rejection...

Continue reading

Form 8.3 – KAZ Minerals plc

Written by Customer Service on . Posted in Mergers And Acquisitions.

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

Continue reading

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2020

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

RANCHO CUCAMONGA, Calif., Nov. 06, 2020 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2020.Third Quarter HighlightsNet revenues of $83.4 million for the third quarterGAAP net income of $3.9 million, or $0.08 per share, for the third quarterAdjusted non-GAAP net income of $7.6 million, or $0.15 per share, for the third quarterDr. Jack Zhang, Amphastar’s President and Chief Executive Officer, commented: “We once again demonstrated growth due to the continued strength of Primatene Mist® and the re-launch of our epinephrine vial product. Additionally, we are very excited about the significant progress on our intranasal epinephrine product as this product once again illustrates our scientific and technical strengths.”_________________ *...

Continue reading

TELUS Corporation announces agreement to acquire Lionbridge AI through TELUS International

Written by Customer Service on . Posted in Public Companies.

Acquisition supports the evolution of TELUS’ digital transformation strategyLionbridge AI to enhance TELUS International’s ability to support leading global technology brands developing the next generation of artificial intelligence (AI) and data annotationVANCOUVER, British Columbia, Nov. 06, 2020 (GLOBE NEWSWIRE) — Today, TELUS Corporation (T-TSX; NYSE-TU), announced that TELUS International, a digital customer experience (CX) innovator that designs, builds and delivers next-generation solutions for global and disruptive brands, has entered into an agreement to acquire Lionbridge AI, a market-leading global provider of crowd-based training data and annotation platform solutions used in the development of AI algorithms to power machine learning. The acquisition will be at a purchase price of approximately C$1.2 billion (approximately...

Continue reading

TELUS Corporation annonce l’acquisition de Lionbridge AI par l’intermédiaire de TELUS International

Written by Customer Service on . Posted in Public Companies.

L’acquisition favorise l’évolution de la stratégie de transformation numérique de TELUSLionbridge AI améliorera la capacité de TELUS International à aider des sociétés technologiques mondiales à développer la prochaine génération de l’intelligence artificielle (IA) et d’annotation des donnéesVANCOUVER, Colombie Britannique, 06 nov. 2020 (GLOBE NEWSWIRE) — Aujourd’hui, TELUS Corporation (TSX : T; NYSE : TU) a annoncé que TELUS International, une entreprise novatrice en matière d’expérience client numérique qui conçoit, élabore et offre des solutions de prochaine génération pour des marques mondiales, a conclu une entente visant l’acquisition de Lionbridge AI, un chef de file qui fournit des solutions de plateforme d’annotation et de données d’apprentissage collaboratives utilisées dans l’élaboration d’algorithmes d’intelligence artificielle...

Continue reading

CORRECTION: Dates of periodic information disclosure of AUGA group, AB for the year 2020 (investor calendar)

Written by Customer Service on . Posted in Public Companies.

Correction: date in Lithuanian announcement was corrected. Correction is made in Lithuanian announcement only.AUGA group, AB (legal entity code: 126264360, registered office address: Konstitucijos pr. 21C, Vilnius; hereinafter – the Company) is planning to announce the results of the Company in the year 2020 as follows:General managerKęstutis Juščius+370 5 233 5340

Continue reading

PATIKSLINIMAS: 2020 m. AUGA group, AB periodinės informacijos atskleidimo datos (investuotojo kalendorius)

Written by Customer Service on . Posted in Public Companies.

Patikslinimas: patikslinta data pranešime. Patikslinimas atliktas tik pranešime lietuvių kalba.AUGA group, AB (juridinio asmens kodas: 126264360, buveinės adresas: Konstitucijos pr. 21C, Vilnius; toliau – Bendrovė) 2020 m. savo veiklos rezultatus planuoja skelbti tokia tvarka:Generalinis direktoriusKęstutis Juščius+370 5 233 5340

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.